ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) TSE: EPI's share price passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $1.66 and traded as low as $1.58. ESSA Pharma shares last traded at $1.58, with a volume of 74,752 shares changing hands.
ESSA Pharma Price Performance
The stock has a market cap of $63.92 million, a P/E ratio of -2.09 and a beta of 1.61. The stock's 50-day moving average is $1.65 and its two-hundred day moving average is $2.59.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.01). On average, analysts anticipate that ESSA Pharma Inc. will post -0.42 EPS for the current fiscal year.
Institutional Trading of ESSA Pharma
A number of large investors have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new stake in shares of ESSA Pharma in the 4th quarter valued at approximately $26,000. Two Sigma Securities LLC bought a new stake in shares of ESSA Pharma in the 4th quarter worth about $29,000. GTS Securities LLC purchased a new position in shares of ESSA Pharma during the 4th quarter worth about $30,000. FNY Investment Advisers LLC bought a new position in ESSA Pharma during the 4th quarter valued at about $44,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in ESSA Pharma in the 4th quarter worth about $47,000. 75.12% of the stock is currently owned by institutional investors.
ESSA Pharma Company Profile
(
Get Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Featured Articles
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
